Could a special PET scan spot returning prostate cancer sooner?

NCT ID NCT07115914

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether adding a PSMA PET scan to the usual MRI can better detect prostate cancer that has come back after focal therapy. Focal therapy treats only the cancerous part of the prostate, but cancer can sometimes return. The PSMA PET scan uses a radioactive dye that sticks to prostate cancer cells, making them show up on images. Researchers will enroll 62 men who have had focal therapy to see if the PSMA PET scan finds more recurrences than MRI alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

PSMA PET/CT scan (radioactive imaging dye)

What this could lead to

If successful, this could make it easier and more accurate to detect prostate cancer that comes back after focal therapy, potentially guiding earlier treatment.

What could go wrong

This is a small, early-stage study (62 participants) focused on imaging accuracy, not treatment. The PSMA PET scan may not prove better than standard MRI, and results may not apply to all prostate cancer patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma disease metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • University of Chicago Medicine Comprehensive Cancer Center

    RECRUITING

    Chicago, Illinois, 60637, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••